According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

Kirkland & Ellis has successfully defended the validity of a pharmaceutical company's patent in London's High Court, ...

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...

In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...

US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...

Ahmedabad: Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...

FibroGen Inc (FGEN) reports significant revenue increases and strategic pivots amid challenges in clinical trials and market ...

Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...